DSM-Firmenich details progress in €500 million buyback, shares in focus on SIX Swiss Exchange

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 15:03.

DSM-Firmenich (CH1216478797) has reported fresh weekly figures for its ongoing share repurchase program. The stock trades on the SIX Swiss Exchange, where investors are tracking the scale and pace of the capital reduction plan as the second quarter draws to a close.IR release on the weekly buyback update

New weekly buyback data

According to the company’s June 23 press release, DSM-Firmenich repurchased 180,000 ordinary shares between June 15 and June 19, 2026.GlobeNewswire publication of the buyback update The shares were bought at an average price of €74.57, corresponding to a total consideration of €13.4 million for the period.

Since the start of the program on March 12, 2026, the company has repurchased 4,184,962 shares for a total of €270.7 million at an average price of €64.69 per share.Company data on aggregate buybacks Of the initial €540 million announced in February, €40 million to cover share-based compensation commitments was completed by March 23, 2026, leaving the bulk of the remaining capacity directed at reducing issued capital.

Program size, timing and market context

The announced buyback framework totals €540 million, split into €40 million for share-based compensation and €500 million for capital reduction, with the latter targeted for completion by the end of the third quarter of 2026.Press release on program parameters The latest weekly purchases therefore bring the company more than halfway towards the capital reduction component in value terms.

On MarketScreener, DSM-Firmenich is tracked alongside other European specialty chemicals and nutrition names, with the site citing a recent indicative price of 69.56 Swiss francs and a year-to-date performance of around 12 percent as of June 23, 2026.MarketScreener snapshot on DSM-Firmenich The same snapshot shows a one-day move of roughly minus 9.7 percent, underlining that the shares have been volatile even as buybacks continue.

How DSM-Firmenich earns its money

DSM-Firmenich generates revenue primarily from nutrition, health and beauty products, with a strong footprint in food ingredients, animal nutrition and fragrance and flavor solutions for consumer goods. Its Human Nutrition & Care division supplies vitamins, premixes and specialty ingredients to food, beverage and dietary supplement producers worldwide.

Where the shares trade today

The DSM-Firmenich shares (CH1216478797) last traded on the SIX Swiss Exchange at around 69.56 Swiss francs on 2026-06-23, 11:00, based on a MarketScreener real-time estimate.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. All data have been compiled with care but without any guarantee.